Melanotan I, Honestly: Afamelanotide Is an Approved Orphan Drug, Not an Injectable Tan

There is exactly one compound in this catalogue that a major regulator has licensed as a finished medicine, and it is not the one the internet thinks. Melanotan I is afamelanotide, sold as Scenesse, a controlled-release implant approved for a rare, exquisitely painful inability to tolerate light.²⁴ Almost everything written about it online concerns a different molecule, a different use, and a different safety story.

Is Melanotan I really the same thing as afamelanotide?

Yes, and the naming is the first place clarity goes to die. “Melanotan I” is laboratory shorthand for a synthetic, more stable analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), a tridecapeptide that differs from the native hormone by a single, stabilising amino-acid substitution.⁸¹⁰ The pharmaceutical name is afamelanotide; the trade name is Scenesse, developed by Clinuvel.²⁶ The European Medicines Agency granted marketing authorisation under exceptional circumstances in 2014, and the US Food and Drug Administration followed in October 2019, both for erythropoietic protoporphyria (EPP).³⁶ That is a genuine regulatory pedigree, and it is the single fact that separates this molecule from the rest of the grey market.

It is also the fact most abused. “EMA- and FDA-approved” is true, but it describes an orphan medicine delivered by a clinician as a subcutaneous implant for a specific genetic disorder. It does not describe a lifestyle injectable, and the gap between those two readings is the entire subject of this piece.²

How does MC1R agonism actually produce photoprotection?

The mechanism is worth stating precisely, because precision is exactly what the marketing strips away. Alpha-MSH binds the melanocortin-1 receptor (MC1R) on melanocytes; receptor activation shifts pigment synthesis toward eumelanin, the brown-black pigment, rather than the reddish pheomelanin.⁷⁸ Eumelanin is the photoprotective species: it absorbs and scatters ultraviolet and visible light and quenches reactive oxygen species.⁵⁷ There is also evidence that MC1R signalling enhances repair of UV-induced DNA damage, so the protection is not pigment alone.¹⁸ Afamelanotide is an MC1R agonist with greater metabolic stability than native alpha-MSH, which is what allows a depot formulation to drive eumelanin production durably rather than in brief pulses.⁴¹⁰

In EPP, the relevance is not vanity. Patients carry defects in the haem-biosynthesis enzyme ferrochelatase, accumulating protoporphyrin IX, a potent photosensitiser.⁵⁷ Ordinary light exposure triggers severe burning pain and tissue damage within minutes.⁵¹³ Increasing eumelanin raises the skin’s tolerance to light by absorbing the wavelengths that drive the phototoxic reaction. The “tan” is incidental; the goal is a photoprotective barrier in people for whom daylight is an injury.

The pigment is the side effect that became a black market; photoprotection was always the point.

What did the EPP trials show, and how is it delivered?

The clinical programme that earned approval studied EPP patients receiving afamelanotide as a small, bioresorbable, controlled-release implant placed subcutaneously, each containing 16 mg of peptide and releasing it steadily over roughly two months rather than as repeated bolus injections.⁴¹⁵ In the pivotal US trial, treated patients recorded markedly more pain-free time in direct sunlight than placebo patients over six months — a median on the order of 69 hours versus 41 — alongside quality-of-life gains in a population that had essentially no prior pharmacological options.⁶¹²

The honest framing of those numbers matters more than the numbers. The primary endpoints were largely patient-reported: time in light, pain diaries, days affected.³¹² These are meaningful to people who live with EPP, but they are subjective and surrogate-heavy by the standards of, say, an oncology endpoint, and conducting blinded placebo trials in a disorder this visible is genuinely difficult. The effect was real but moderate, the trial populations were small because the disease itself is rare, and the licence rests on that orphan-scale evidence rather than on a large, hard-endpoint dataset.³¹⁴

1 in 75,000 a commonly cited EPP prevalence — though biobank data suggest the true figure may be several-fold higher due to underdiagnosis⁵

How is this different from Melanotan II?

This is the distinction that the marketplace deliberately blurs. Melanotan I (afamelanotide) is the selective, clinically developed cousin: a registered drug with a defined formulation, a regulator-reviewed dossier, and a narrow licensed use.²⁶ Melanotan II is its unapproved relative — a cyclic, less selective melanocortin analogue that activates a broader range of melanocortin receptors, which is precisely why it produces the off-target effects (notably libido and erectile changes) that fuelled its underground popularity alongside tanning.¹

¹⁵

The two “Melanotans” share a target family and a name but diverge on selectivity, regulation, and risk; conflating them is the central error this catalogue page exists to prevent.

What does an honest reading of the evidence allow?

Several things should be said plainly. First, afamelanotide is approved for EPP and only EPP; no regulator has endorsed it for cosmetic tanning³⁶, and “approved” carries no implication of safety outside its licensed context, population, and formulation. Second, the EPP evidence base, while sufficient for an orphan drug, is modest in size and leans on subjective endpoints.⁷¹² Third, long-term consequences of MC1R-driven pigmentation in healthy people pursued for cosmetic ends are simply not characterised in controlled trials¹¹⁵; the safety reassurance from the EPP programme does not transfer to that setting.

The Melanotan II picture is messier still. The harms attached to it come largely from individual case reports — priapism, nausea, rapidly appearing atypical naevi — and from the inherent hazards of an unregulated, often non-sterile, self-prepared product. The melanoma link in particular is an association, not established causation; at least one review attributes the apparent excess risk to the heavier UV exposure that tanning-peptide users seek out rather than to the peptide itself.¹ Honesty cuts both ways: the case against Melanotan II is strong on grounds of being unapproved, off-target, and impure, without needing to overstate a contested melanoma mechanism.

For the wider context, the broader melanocortin literature shows how receptor selectivity governs both efficacy and off-target liability¹²; readers can see our melanocortins editorial and the adjacent skin and GHK-Cu cluster for that map. Melanotan I sits at the disciplined end of that spectrum; Melanotan II sits at the reckless end. The catalogue lists both, and the difference is pharmacological, not promotional. Where the cosmetic-tanning narrative meets the actual data, the data are thin to absent.

None of the above describes a product for use. The licensed medicine is Scenesse, an implant placed by a physician for a diagnosed disorder¹⁴¹⁵; that is categorically distinct from research-grade reference material, which exists only to be characterised, not administered. For that purpose the questions worth asking are about identity and purity: a current certificate of analysis, HPLC purity, and mass-spectrometric confirmation of the correct sequence and mass.¹¹ Those documents are the only properties a buyer can actually verify, and on a molecule this routinely misrepresented, verification is the whole job.